CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质瘤中肿瘤来源的 LAIR-1 通过双重机制驱动纤维化并阻断免疫细胞招募，导致癌症免疫排斥

A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma.

免疫基因组图谱揭示儿童脑肿瘤的基因治疗靶点

Immunogenomic profiling reveals targets for gene therapy in pediatric brain tumors.

这种整合分析方法识别出 pDMG 中可靶向的通路、表面抗原和新抗原，支持 CAR-T 和 TCR-T 疗法的开发。这些发现还提示其可能适用于其他携带相同突变的癌症。

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

1 型神经纤维瘤病：遗传机制与治疗创新进展

Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation.

定义治疗抵抗性脑癌：通过基因筛选识别癌基因驱动的免疫调节和治疗抵抗

Defining treatment-resistant brain cancer: Genetic screening to identify oncogene-driven immunomodulation and therapy resistance.

仿生永生化间充质干细胞纳米颗粒经 CD73 靶向和化疗抑制原位术后胶质瘤

Biomimetic immortalized mesenchymal stem cell-based nanoparticles suppress orthotopic postsurgical glioma via CD73 targeting and chemotherapy.

识别与高级别胶质瘤免疫细胞重编程相关的免疫调节性 lncRNA 特征

Identification of an immunomodulatory lncRNA signature associated with immune cell reprogramming in high-grade glioma.

胶质母细胞瘤免疫治疗的挑战与新兴策略

Challenges and Emerging Strategies of Immunotherapy for Glioblastoma.

间充质干细胞来源细胞外囊泡的系统综述：胶质母细胞瘤的潜在治疗

A Systematic Review of Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Treatment for Glioblastoma.

MSC 来源的 EVs 是治疗 GBM 的一种有前景的策略，可通过多种机制抑制肿瘤生长并增强治疗效果。

mRNA 疫苗对胶质母细胞瘤和人类癌症的变革性潜力：技术进步与向临床试验的转化

The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.